Medpace Holdings, Inc. MEDP AVAI — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medpace Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Medpace Holdings, Inc.’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medpace Holdings, Inc.'s avai — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medpace Holdings, Inc.'s AVAI — total revenue?
- Medpace Holdings, Inc. (MEDP) reported AVAI — total revenue of $38.02M in Q1 2026.
- How has Medpace Holdings, Inc.'s AVAI — total revenue changed year-over-year?
- Medpace Holdings, Inc.'s AVAI — total revenue increased by 22.4% year-over-year, from $31.06M to $38.02M.
- What is the long-term trend for Medpace Holdings, Inc.'s AVAI — total revenue?
- Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s AVAI — total revenue has grown at a 5.0% compound annual growth rate (CAGR), from $110.98M to $134.94M.
- What does AVAI — total revenue mean?
- The total revenue earned from providing clinical trial and development services for antiviral and anti-infective drug programs.
- How do you interpret AVAI — total revenue?
- An increase suggests growing demand for clinical research services in the infectious disease sector and successful project execution, while a decrease may indicate a slowdown in client R&D spending or increased competition in this therapeutic niche.
- How does AVAI — total revenue compare across companies?
- Peers in the contract research organization industry typically report revenue by therapeutic area or service type, making this comparable to specialized infectious disease clinical trial revenue segments at other global CROs.